RS49831B - Farmaceutske kompozicije tizoksanida i nitazoksanida - Google Patents

Farmaceutske kompozicije tizoksanida i nitazoksanida

Info

Publication number
RS49831B
RS49831B YUP-571/99A YU57199A RS49831B RS 49831 B RS49831 B RS 49831B YU 57199 A YU57199 A YU 57199A RS 49831 B RS49831 B RS 49831B
Authority
RS
Serbia
Prior art keywords
pharmacedtical
tizoxanide
nitazoxanide
compositions
compound
Prior art date
Application number
YUP-571/99A
Other languages
English (en)
Inventor
Jean-Francois Rossignol
Original Assignee
Romark Laboratories L.C.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/887,809 external-priority patent/US5965590A/en
Priority claimed from US08/887,810 external-priority patent/US5856348A/en
Application filed by Romark Laboratories L.C., filed Critical Romark Laboratories L.C.,
Priority claimed from PCT/US1998/009229 external-priority patent/WO1998050035A1/en
Publication of YU57199A publication Critical patent/YU57199A/xx
Publication of RS49831B publication Critical patent/RS49831B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Farmaceutska kompozicija za oralnu primenu koja kao aktivno sredstvo barem jedno jedinjenje koje je odabrano iz grupe koju čine: jedinjenje formule (I) i jedinjenje formule (II) gde je pomenuto aktivno sredstvo u obliku aktivnih čestica čija je veličina manja od 200 μm i gde je srednja vrednost veličine čestice veća od 10μm.Prijava sadrži još 41 patentni zahtev.
YUP-571/99A 1997-05-07 1998-05-06 Farmaceutske kompozicije tizoksanida i nitazoksanida RS49831B (sr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/852,447 US5968961A (en) 1997-05-07 1997-05-07 Pharmaceutical compositions of tizoxanide and nitazoxanide
US08/887,809 US5965590A (en) 1994-09-08 1997-07-03 Method for treatment of opportunistic infections with pharmaceutical compositions of tizoxanide and nitazoxanide
US08/887,810 US5856348A (en) 1994-09-08 1997-07-03 Method for treatment of trematodes with pharmaceutical compositions of tizoxanide and nitazoxanide
PCT/US1998/009229 WO1998050035A1 (en) 1997-05-07 1998-05-06 Pharmaceutical compositions of tizoxanide and nitazoxanide

Publications (2)

Publication Number Publication Date
YU57199A YU57199A (sr) 2002-08-12
RS49831B true RS49831B (sr) 2008-08-07

Family

ID=25313357

Family Applications (2)

Application Number Title Priority Date Filing Date
RSP-2007/0379A RS50046B (sr) 1997-05-07 1998-05-06 Farmaceutske kompozicije tizoksanida i nitazoksanida
YUP-571/99A RS49831B (sr) 1997-05-07 1998-05-06 Farmaceutske kompozicije tizoksanida i nitazoksanida

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RSP-2007/0379A RS50046B (sr) 1997-05-07 1998-05-06 Farmaceutske kompozicije tizoksanida i nitazoksanida

Country Status (11)

Country Link
US (2) US5968961A (sr)
AR (1) AR008355A1 (sr)
BG (1) BG65679B1 (sr)
CO (1) CO4950538A1 (sr)
CU (1) CU23318A7 (sr)
ID (1) ID24828A (sr)
LT (1) LT4751B (sr)
PL (1) PL193556B1 (sr)
RO (1) RO122247B1 (sr)
RS (2) RS50046B (sr)
ZA (1) ZA983849B (sr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7125568B2 (en) 2001-08-23 2006-10-24 Sung Michael T Lipophilic drug compositions
CA2467321A1 (en) * 2004-05-14 2005-11-14 Paul J. Santerre Polymeric coupling agents and pharmaceutically-active polymers made therefrom
UA90864C2 (en) 2004-09-09 2010-06-10 Ромарк Лебораториз, Л.К. Halogenated benzamide derivatives
CA2604640A1 (en) * 2005-04-12 2006-10-19 Romark Laboratories L.C. Methods for treating diseases through interruption of protein maturation, compounds that inhibit the function of molecular chaperones such as protein disulfide isomerases or interfere with glycosylation, pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents
ZA200806310B (en) 2006-01-09 2009-12-30 Romark Lab Lc Viral hepatitis treatment
JP5726766B2 (ja) 2009-02-13 2015-06-03 ロマーク ラボラトリーズ エル．シー． ニタゾキサニドの制御放出医薬配合物
SG10201402281WA (en) 2009-05-12 2014-07-30 Romark Lab Lc Haloalkyl heteroaryl benzamide compounds
EA030679B1 (ru) 2009-06-26 2018-09-28 РОМАРК ЛЭБОРЕТЕРИЗ Эл.Си. Соединения и способы лечения гриппа
DK2709453T3 (da) 2011-05-16 2020-01-20 Romark Laboratories Lc Anvendelse af thiazolid-forbindelser til forebyggelse og behandling af virussygdomme, cancer og sygdomme forårsaget af intracellulære infektioner
BR112014018149B1 (pt) * 2012-01-27 2020-09-29 Siegfried Rhein S.A. De C.V Composição farmacêutica de nitazoxanida
US20140306689A1 (en) 2013-04-10 2014-10-16 Texas Instruments, Incorporated High resolution current pulse analog measurement
CN107105660A (zh) 2014-11-11 2017-08-29 罗马克实验室有限公司 使用替唑尼特、其类似物或盐的前药的治疗组合物和治疗方法
PL3436074T3 (pl) 2016-03-31 2020-11-02 Romark Laboratories, L.C. Związki z grupą tiazolidynową do leczenia zakażeń wirusowych
DK3442580T3 (da) 2016-04-11 2020-12-21 Genfit Fremgangsmåder til behandling af kolestatiske og fibrotiske sygdomme
US11173149B2 (en) 2017-04-18 2021-11-16 Romark Laboratories L.C. Inhibition of protein disulfide-isomerase A3
US20210113457A1 (en) 2018-02-02 2021-04-22 Ripple Therapeutics Corporation Glass formulations and uses thereof
MX2022013665A (es) 2020-05-01 2022-11-30 Ripple Therapeutics Corp Composiciones y metodos heterodimeros para el tratamiento de trastornos oculares.
WO2022020243A1 (en) 2020-07-20 2022-01-27 Romark Laboratories L.C. Crystalline salts of tizoxanide and 2-hydroxy-n-(5-chloro-1,3-thiazol-2-yl)benzamide (rm-4848) with ethanolamine, morpholine, propanolamine, piperazine and n-methylpiperazine
AU2021333566A1 (en) 2020-08-24 2023-03-16 Romark Laboratories L.C. Use of thiazolides against coronaviruses

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1437800A (en) * 1973-08-08 1976-06-03 Phavic Sprl Derivatives of 2-benzamido-5-nitro-thiazoles
US4315018A (en) * 1978-12-07 1982-02-09 Rossignol Jean F Specific parasiticidal use of 2-benzamido-5-nitro-thiazole derivatives
US5496809A (en) * 1989-05-10 1996-03-05 Bristol-Myers Squibb Co Stable solutions of rebeccamycin analog
US5578621A (en) * 1994-09-08 1996-11-26 Romark Lab Lc Benzamide derivatives
US5387598A (en) * 1994-04-13 1995-02-07 Rossignol; Jean-Francois Composition and galenic formulation suitable for combatting affections of the lower abdomen
CZ287002B6 (en) 1994-04-13 2000-08-16 Rossignol Jean Franaois Benzamide derivative, pharmaceutical preparation containing thereof and use of the derivative

Also Published As

Publication number Publication date
CU23318A7 (es) 2008-10-22
RS50046B (sr) 2008-11-28
YU57199A (sr) 2002-08-12
LT4751B (lt) 2001-01-25
US5968961A (en) 1999-10-19
RO122247B1 (ro) 2009-03-30
PL193556B1 (pl) 2007-02-28
ZA983849B (en) 1999-08-27
CO4950538A1 (es) 2000-09-01
US6117894A (en) 2000-09-12
BG65679B1 (bg) 2009-06-30
RS20070379A (en) 2008-06-05
ID24828A (id) 2000-08-24
LT99141A (en) 2000-08-25
AR008355A1 (es) 2000-01-19

Similar Documents

Publication Publication Date Title
RS49831B (sr) Farmaceutske kompozicije tizoksanida i nitazoksanida
YU13695A (sh) Upotreba 2-fenil-3-aroilbenzotiofena i njihove farmaceutske formulacije
YU49698A (sh) Smeše koje sadrže tetrahidrolipstatin
AU4264396A (en) Cosmetic or pharmaceutical compositions containing mangiferin or derivatives thereof
ATE165971T1 (de) Ein definiertes lipidsystem enthaltende pharmazeutische zusammensetzung
ATE324907T1 (de) Verbindung und arzneizusammensetzung zur verabreichung von wirkstoffen
ATE271383T1 (de) Pulverformulierung zur inhalation
BR0107869A (pt) Composições farmacêuticas eletrogiradas
CA2346001A1 (en) Controlled release nanoparticulate compositions
DK0642344T3 (da) Stabilt tørt pulver af hydratiseret cephalosporin til oral suspensionsformulering.
RS50303B (sr) Farmaceutska kompozicija nimesulida sa kontrolisanim oslobađanjem
RS50937B (sr) Farmaceutska kompozicija koja sadrži metformin i glibenklamid za lečenje šećerne bolesti tipa ii
YU45098A (sh) Kompozicije koje sadrže antifungicidno sredstvo i acetatni pufer
KR970705553A (ko) 디히드로벤조푸란, 및 항염증 약물로서 유용한 관련 화합물(dihydrobenzofuran and related compounds useful as anti-inflammatory agents)
DE69925293D1 (de) Sprühbeschichtete mikropartikel für nadellose spritzen
ME00530B (me) Farmaceutske kompozicije tizoksanida i nitazoksanida
HUP0203226A2 (hu) Hatóanyagként benzamidszármazékot tartalmazó gyógyszerkészítmény
DE69827466D1 (de) Geschmacksneutrale pharmazeutische zusammensetzungen
IL114968A (en) 1,4-dihydropyridine compounds and pharmaceutical compositions containing them
GEP20032975B (en) Echinocandin Derivatives, Preparation Method and Pharmaceutical Composition
AU2001237768A1 (en) Pharmaceutical composition for treatment and prevention of liver fibrosis and cirrhosis
IL147901A0 (en) Phenanthroline-7-one derivatives and their therapeutic uses
ECSP982778A (es) Nuevas composiciones que tienen actividad terapeutica en forma de particulas
MXPA99004343A (es) Proceso para la preparacion de una composicion farmaceutica oral, composicion farmaceutica oral y equipo que comprende una composicion farmaceutica.
IT1314204B1 (it) Complessi di rutenio con elevata attivita' antitumorale